Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

The Use of Computational Methods in the Discovery and Design of Kinase Inhibitors

Author(s): John R. Woolfrey and G. Scott Weston

Volume 8, Issue 17, 2002

Page: [1527 - 1545] Pages: 19

DOI: 10.2174/1381612023394304

Price: $65

Abstract

The recent success of the first FDA-approved small-molecule tyrosine kinase inhibitor Gleevec (STI-571, imatinib mesylate) in the treatment of chronic myelogenous leukemia (CML) has focused attention on the potential therapeutic usefulness of inhibitors of other kinase targets. This review shall highlight recent applications of computational chemistry methods, comprising both ligand-based and structure-based approaches, in the discovery and design of kinase inhibitors. In particular, we will focus on ATP-competitive inhibitors of selected kinase targets of therapeutic importance.

Keywords: kinase inhibitor, gleevec, imatinib mesylate, cml, chronic myelogenous leuremig, comfa, comsia

Next »

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy